

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

WEDNESDAY, NOVEMBER 29, 1967

U.S. SENATE,
MONOPOLY SUBCOMMITTEE OF THE
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C.

The subcommittee met, pursuant to recess, at 10:05 a.m., in room 318, Old Senate Office Building, Senator Gaylord Nelson (chairman of the subcommittee) presiding.

Present: Senators Nelson and Hatfield.

Also present: Benjamin Gordon, staff economist; James H. Grossman, minority counsel; Susan H. Hewman, research assistant; and William B. Cherkasky, legislative director, staff of Senator Nelson.

Senator NELSON. The meeting of the subcommittee will come to order.

The committee welcomes these witnesses representing the Pharmaceutical Manufacturers Association. I understand the first witness will be Dr. Leslie Lueck; the second witness, Dr. Slessor; the third witness, Dr. Scheele; the fourth witness, Dr. Van Riper; and the fifth witness, Mr. Blazey.¹

Dr. Lueck, the committee welcomes your appearance today.

Did you submit to the committee a biographical sketch?

STATEMENT OF LESLIE M. LUECK, PH. D., DIRECTOR OF QUALITY CONTROL, PARKE, DAVIS & CO., DETROIT, MICH.; ACCOMPANIED BY LLOYD N. CUTLER, SPECIAL COUNSEL, PHARMACEUTICAL MANUFACTURERS ASSOCIATION, WASHINGTON, D.C.

Dr. LUECK. Yes, I did—a brief one.

Mr. CUTLER. It is at the beginning of Dr. Lueck's statement, Mr. Chairman.

Senator NELSON. Dr. Lueck, we welcome your appearance today. The committee is aware of your distinguished record, including your association with the great State of Wisconsin and its university.

You may present your testimony in any way you see fit. I assume you have no objection if we have questions during the presentation of your statement.

Dr. LUECK. No, sir; I do not.

Senator NELSON. The full statement will be printed in the record. If at any stage you feel it would expedite matters to extemporize in

¹ Dr. Lueck, Dr. Slessor, Dr. Scheele, Dr. Van Riper, and Mr. Blazey were originally scheduled for appearance with Mr. C. Joseph Stetler, president, Pharmaceutical Manufacturers Association, hearing date, November 16, 1967, Competitive Problems in the Drug Industry, part 4.